$0.42
-0.01(-1.60%)
Mkt Cap $580.9K
$0.34
$1.11
52-Week Range
At a Glance
AI-generated6-K
XORTX Therapeutics Inc. announced that its previously declared share consolidation of one new share for every five old shares will become effective on April 6, 2026, following receipt of required exchange approvals.$580.9K
Market Cap
—
Revenue
-$2M
Net Income
Employees2
Fundamentals
How The Business Makes Money
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.
Industry Biotechnology
Activity
What Changed Recently
Company Profile
CIK0001729214
ISINCA98420Q3061
CUSIP98420Q207
Address421 – 7th Avenue SW, Vancouver, BC, T2P 4K9, CA
SEC EDGAR